HEPACUTE
Host and viral factors in acute hepatitis C
| Coordinatore | KLINIKUM DER UNIVERSITAT MUNCHEN
Organization address
address: MARCHIONINISTRASSE 15 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 3˙854˙861 € |
| EC contributo | 2˙999˙500 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2010-single-stage |
| Funding Scheme | CP-FP-SICA |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-11-01 - 2014-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
KLINIKUM DER UNIVERSITAT MUNCHEN
Organization address
address: MARCHIONINISTRASSE 15 contact info |
DE (MUNCHEN) | coordinator | 264˙500.00 |
| 2 |
THE UNIVERSITY OF BIRMINGHAM
Organization address
address: Edgbaston contact info |
UK (BIRMINGHAM) | participant | 335˙500.00 |
| 3 |
AZIENDA OSPEDALIERO-UNIVERSITARIA DI PARMA
Organization address
address: VIA GRAMSCI 14 contact info |
IT (PARMA) | participant | 286˙500.00 |
| 4 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 264˙500.00 |
| 5 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 226˙035.00 |
| 6 |
MEDIZINISCHE HOCHSCHULE HANNOVER
Organization address
address: Carl-Neuberg-Strasse 1 contact info |
DE (HANNOVER) | participant | 197˙000.00 |
| 7 |
FUNDACION PARA LA INVESTIGACION MEDICA APLICADA FIMA
Organization address
address: AVENIDA DE PIO XII 55 contact info |
ES (PAMPLONA) | participant | 172˙500.00 |
| 8 |
THE HOLDING COMPANY FOR BIOLOGICAL PRODUCTS & VACCINES LLC
Organization address
address: WAZARET EL ZERAA - ALGOUZA 51 contact info |
EG (GIZA) | participant | 168˙000.00 |
| 9 |
INSERM - TRANSFERT SA
Organization address
address: Rue Watt 7 contact info |
FR (PARIS) | participant | 165˙965.00 |
| 10 |
HOSPICES CANTONAUX CHUV
Organization address
address: Rue du Bugnon 21 contact info |
CH (LAUSANNE) | participant | 148˙000.00 |
| 11 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 148˙000.00 |
| 12 |
National Research Center
Organization address
address: El Buhouth street contact info |
EG (Cairo) | participant | 142˙000.00 |
| 13 |
MOSAIQUES DIAGNOSTICS GMBH
Organization address
address: Mellendorfer Strasse 7-9 contact info |
DE (HANNOVER) | participant | 123˙000.00 |
| 14 |
KLINIKUM DER UNIVERSITAET ZU KOELN
Organization address
address: Kerpener Strasse 62 contact info |
DE (KOELN) | participant | 118˙000.00 |
| 15 |
Institut Pasteur Du Maroc
Organization address
address: Place Louis Pasteur 1 contact info |
MA (Casablanca) | participant | 89˙000.00 |
| 16 |
MENOUFIYA UNIVERSITY
Organization address
address: GAMAL ABDEL NASER STREET contact info |
EG (MENOUFIYA) | participant | 82˙000.00 |
| 17 |
UNIVERSITE DE GENEVE
Organization address
address: Rue du General Dufour 24 contact info |
CH (GENEVE) | participant | 69˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Chronic hepatitis C is one of the most common chronic viral infections of humans and a major cause of chronic liver disease, cirrhosis and liver cancer. Still about 4 million new infections occur world-wide each year with 50-85% of patients progressing to chronic hepatitis C. Currently there is no marker to predict spontaneous viral clearance and to guide treatment decisions. The major objectives of the HepaCute proposal are to develop biomarkers predicting the outcome of acute hepatitis C, improving the management of the related patients and thus decreasing the health burden of hepatitis C in Europe and Mediterranean partner countries (MPC). The HepaCute consortium has evolved from a series of EC-funded projects on hepatitis C (HCVacc/HepCvax/Virgil/HEPACIVAC) and consists of world leading experts in HCV epidemiology, immunology, and virology, including partners from Egypt and Morocco, who have strongly influenced the current management of patients with acute hepatitis C in their respective regions, and contributed considerably to our understanding of mechanisms of spontaneous viral clearance. The HepaCute proposal is closely connected to ongoing national, European, and Egyptian networks on HCV research (HepNet, EASL, STDF), which will support HepaCute to make it a success.Together with another pertinent EU-funded research project, SPHINX, it actively contributes to coordinating EU-funded hepatitis C research with pertinent research projects funded in the MCP countries, in particular with hepatitis research projects funded under the Egyptian Science and Technology Development Fund (STDF). Within HepaCute the most innovative technologies will be employed such as genome-wide association studies, transcriptomics, proteomics, and ultra-deep sequencing to better understand the early events in acute hepatitis C and to translate these results into readily practicable diagnostic tools to predict spontaneous viral clearance. HepaCute has firmly integrated partners from Egypt and Morocco with preexisting research collaborations with European partners into the scientific research programm and we expect this continuing partnership between European and Mediterranean countries to have a strong impact on the care of patients with acute hepatitis C both in Europe and MPC.'
Introduzione (Teaser)
Chronic hepatitis C infection is a major issue in certain parts of the world. Understanding how the virus evades the host immune system could improve prognosis and lead to novel therapeutic interventions.